These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

387 related articles for article (PubMed ID: 31445197)

  • 1. Challenging the recalcitrant disease-developing molecularly driven treatments for small cell lung cancer.
    Mak DWS; Li S; Minchom A
    Eur J Cancer; 2019 Sep; 119():132-150. PubMed ID: 31445197
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Notch pathway in small-cell lung cancer: from preclinical evidence to therapeutic challenges.
    Leonetti A; Facchinetti F; Minari R; Cortellini A; Rolfo CD; Giovannetti E; Tiseo M
    Cell Oncol (Dordr); 2019 Jun; 42(3):261-273. PubMed ID: 30968324
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Targeted Therapy and Immune Therapy for Small Cell Lung Cancer.
    Gadgeel SM
    Curr Treat Options Oncol; 2018 Sep; 19(11):53. PubMed ID: 30203184
    [TBL] [Abstract][Full Text] [Related]  

  • 4. DLL3: an emerging target in small cell lung cancer.
    Owen DH; Giffin MJ; Bailis JM; Smit MD; Carbone DP; He K
    J Hematol Oncol; 2019 Jun; 12(1):61. PubMed ID: 31215500
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Bromodomain and hedgehog pathway targets in small cell lung cancer.
    Kaur G; Reinhart RA; Monks A; Evans D; Morris J; Polley E; Teicher BA
    Cancer Lett; 2016 Feb; 371(2):225-39. PubMed ID: 26683772
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Unravelling the biology of SCLC: implications for therapy.
    Sabari JK; Lok BH; Laird JH; Poirier JT; Rudin CM
    Nat Rev Clin Oncol; 2017 Sep; 14(9):549-561. PubMed ID: 28534531
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Targeting the Notch signaling pathway and the Notch ligand, DLL3, in small cell lung cancer.
    Zhang H; Yang Y; Li X; Yuan X; Chu Q
    Biomed Pharmacother; 2023 Mar; 159():114248. PubMed ID: 36645960
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Characteristics of Notch signaling pathway and its correlation with immune microenvironment in SCLC.
    Li W; Ye L; Huang Y; Zhou F; Wu C; Wu F; He Y; Li X; Wang H; Xiong A; Gao G; Wang L; Su C; Ren S; Chen X; Zhou C
    Lung Cancer; 2022 May; 167():25-33. PubMed ID: 35381444
    [TBL] [Abstract][Full Text] [Related]  

  • 9. DLL3 is regulated by LIN28B and miR-518d-5p and regulates cell proliferation, migration and chemotherapy response in advanced small cell lung cancer.
    Huang J; Cao D; Sha J; Zhu X; Han S
    Biochem Biophys Res Commun; 2019 Jun; 514(3):853-860. PubMed ID: 31079917
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Bromodomain Protein-directed Agents and MYC in Small Cell Lung Cancer.
    Hamilton G; Stickler S; Rath B
    Curr Cancer Drug Targets; 2024; 24(9):930-940. PubMed ID: 38275056
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Analysis of DLL3 and ASCL1 in Surgically Resected Small Cell Lung Cancer (HOT1702).
    Furuta M; Sakakibara-Konishi J; Kikuchi H; Yokouchi H; Nishihara H; Minemura H; Harada M; Yamazaki S; Akie K; Fujita Y; Takamura K; Kojima T; Harada T; Minami Y; Watanabe N; Oizumi S; Suzuki H; Nishimura M; Dosaka-Akita H; Isobe H;
    Oncologist; 2019 Nov; 24(11):e1172-e1179. PubMed ID: 31068386
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Combined DLL3-targeted bispecific antibody with PD-1 inhibition is efficient to suppress small cell lung cancer growth.
    Chen X; Amar N; Zhu Y; Wang C; Xia C; Yang X; Wu D; Feng M
    J Immunother Cancer; 2020 Jun; 8(1):. PubMed ID: 32554616
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Second-line treatments of small-cell lung cancers.
    Baize N; Monnet I; Greillier L; Quere G; Kerjouan M; Janicot H; Vergnenegre A; Auliac JB; Chouaid C
    Expert Rev Anticancer Ther; 2017 Nov; 17(11):1033-1043. PubMed ID: 28849951
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Elevated Cellular PD1/PD-L1 Expression Confers Acquired Resistance to Cisplatin in Small Cell Lung Cancer Cells.
    Yan F; Pang J; Peng Y; Molina JR; Yang P; Liu S
    PLoS One; 2016; 11(9):e0162925. PubMed ID: 27610620
    [TBL] [Abstract][Full Text] [Related]  

  • 15. ATR inhibition activates cancer cell cGAS/STING-interferon signaling and promotes antitumor immunity in small-cell lung cancer.
    Taniguchi H; Chakraborty S; Takahashi N; Banerjee A; Caeser R; Zhan YA; Tischfield SE; Chow A; Nguyen EM; Villalonga ÁQ; Manoj P; Shah NS; Rosario S; Hayatt O; Qu R; de Stanchina E; Chan J; Mukae H; Thomas A; Rudin CM; Sen T
    Sci Adv; 2024 Sep; 10(39):eado4618. PubMed ID: 39331709
    [TBL] [Abstract][Full Text] [Related]  

  • 16. HSP90 inhibitor (NVP-AUY922) enhances the anti-cancer effect of BCL-2 inhibitor (ABT-737) in small cell lung cancer expressing BCL-2.
    Yang H; Lee MH; Park I; Jeon H; Choi J; Seo S; Kim SW; Koh GY; Park KS; Lee DH
    Cancer Lett; 2017 Dec; 411():19-26. PubMed ID: 28987383
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Development of molecularly targeted agents and immunotherapies in small cell lung cancer.
    Sharp A; Bhosle J; Abdelraouf F; Popat S; O'Brien M; Yap TA
    Eur J Cancer; 2016 Jun; 60():26-39. PubMed ID: 27060747
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Small Cell Lung Cancer Screen of Oncology Drugs, Investigational Agents, and Gene and microRNA Expression.
    Polley E; Kunkel M; Evans D; Silvers T; Delosh R; Laudeman J; Ogle C; Reinhart R; Selby M; Connelly J; Harris E; Fer N; Sonkin D; Kaur G; Monks A; Malik S; Morris J; Teicher BA
    J Natl Cancer Inst; 2016 Oct; 108(10):. PubMed ID: 27247353
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy and Safety of Rovalpituzumab Tesirine in Third-Line and Beyond Patients with DLL3-Expressing, Relapsed/Refractory Small-Cell Lung Cancer: Results From the Phase II TRINITY Study.
    Morgensztern D; Besse B; Greillier L; Santana-Davila R; Ready N; Hann CL; Glisson BS; Farago AF; Dowlati A; Rudin CM; Le Moulec S; Lally S; Yalamanchili S; Wolf J; Govindan R; Carbone DP
    Clin Cancer Res; 2019 Dec; 25(23):6958-6966. PubMed ID: 31506387
    [TBL] [Abstract][Full Text] [Related]  

  • 20. lncRNAs as Potential Targets in Small Cell Lung Cancer: MYC -dependent Regulation.
    Tokgun O; Tokgun PE; Inci K; Akca H
    Anticancer Agents Med Chem; 2020; 20(17):2074-2081. PubMed ID: 32698750
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.